Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Expert Calls Attention to Treatment-Emergent AEs in Follicular Lymphoma

January 29th 2020

Lawrence D. Kaplan, MD, discusses standard frontline treatment in follicular lymphoma, toxicities of some of the newer agents, and preliminary data with bispecific antibodies.

Brentuximab Vedotin Leads Treatment Progress in Hodgkin Lymphoma

January 28th 2020

Syed Rizvi, MD, discusses recent therapeutic advances in advanced-stage Hodgkin lymphoma.

Targeted Therapy Shifts AML Paradigm, But More Work Lies Ahead

January 28th 2020

Prapti Patel, MD, discusses available and emerging treatment options for patients with acute myeloid leukemia.

Novel Agents Under Investigation for AML

January 28th 2020

Immune Checkpoint Inhibitors for AML

January 28th 2020

Gemtuzumab Ozogamicin for CD33+ AML and APL

January 28th 2020

The Future Landscape of Follicular Lymphoma Treatment

January 28th 2020

Differentiation Syndrome and IDH1/2 Inhibitors

January 28th 2020

IDH1/2 Inhibitors in AML

January 28th 2020

Phase Ib Polatuzumab Vedotin Trial

January 28th 2020

Relapsed/Refractory FLT3-Mutated AML

January 28th 2020

The Phase III GADOLIN Trial

January 28th 2020

Second-Generation FLT3 Inhibitors for AML

January 28th 2020

Previously Untreated FL: Obinutuzumab Plus Lenalidomide

January 28th 2020

The Phase II EZH2 Inhibitor Trial

January 28th 2020

Previously Untreated FLT3-Mutated AML

January 28th 2020

CPX-351 for Secondary AML

January 28th 2020

Sequencing Strategies for Later-Line Therapy

January 28th 2020

Venetoclax-Based Chemotherapy Combinations in AML

January 28th 2020

The DYNAMO Later-Line Regimen

January 28th 2020